Literature DB >> 20396932

Oral anticoagulation in the hospital: analysis of patients at risk.

Nancy L Dawson1, Dusko Klipa, Angela K O'Brien, Julia E Crook, Melanie W Cucchi, Alden K Valentino.   

Abstract

Warfarin is one of the most commonly used medications associated with adverse events. Warfarin therapy is often initiated or continued in the hospital, yet hospitalization increases the risk of poor anticoagulation control with warfarin. To help understand this, we retrospectively reviewed the records of patients admitted to our hospital during a 6-month period who were given at least one dose of warfarin. To explore factors that may have contributed to poor anticoagulation control, we compared characteristics of patients with an international normalized ratio (INR) ≥ 5 at some point during hospitalization with those of a group of matched controls who also received warfarin and had INR <5. Among the 35 patients identified who had an INR ≥ 5, concomitant use of antibiotics was more common than among 105 matched controls; improper warfarin dosing also appeared to contribute to the high INRs. These findings indicate possible targets for intervention to improve patient safety.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20396932     DOI: 10.1007/s11239-010-0473-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  12 in total

1.  Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Hirsh; Gordon Guyatt; Gregory W Albers; Robert Harrington; Holger J Schünemann
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

2.  A randomized trial comparing 5-mg and 10-mg warfarin loading doses.

Authors:  M A Crowther; J B Ginsberg; C Kearon; L Harrison; J Johnson; M P Massicotte; J Hirsh
Journal:  Arch Intern Med       Date:  1999-01-11

3.  Comparison of a single end point to determine optimal initial warfarin dosing (5 mg versus 10 mg) for venous thromboembolism.

Authors:  Rene Quiroz; Marie Gerhard-Herman; Joshua M Kosowsky; Stacia M DeSantis; Nils Kucher; Sylvia C McKean; Samuel Z Goldhaber
Journal:  Am J Cardiol       Date:  2006-06-28       Impact factor: 2.778

4.  Optimization of inpatient warfarin therapy: impact of daily consultation by a pharmacist-managed anticoagulation service.

Authors:  W E Dager; J M Branch; J H King; R H White; R S Quan; N A Musallam; T E Albertson
Journal:  Ann Pharmacother       Date:  2000-05       Impact factor: 3.154

5.  The risk of overanticoagulation with antibiotic use in outpatients on stable warfarin regimens.

Authors:  Jeffrey J Glasheen; Randolph V Fugit; Allan V Prochazka
Journal:  J Gen Intern Med       Date:  2005-07       Impact factor: 5.128

6.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

7.  Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Authors:  Mitchell K Higashi; David L Veenstra; L Midori Kondo; Ann K Wittkowsky; Sengkeo L Srinouanprachanh; Fred M Farin; Allan E Rettie
Journal:  JAMA       Date:  2002-04-03       Impact factor: 56.272

Review 8.  Initiating warfarin therapy: 5 mg versus 10 mg.

Authors:  Courtney D Eckhoff; Robert J Didomenico; Nancy L Shapiro
Journal:  Ann Pharmacother       Date:  2004-11-02       Impact factor: 3.154

Review 9.  Pharmacist-provided anticoagulation management in United States hospitals: death rates, length of stay, Medicare charges, bleeding complications, and transfusions.

Authors:  C A Bond; Cynthia L Raehl
Journal:  Pharmacotherapy       Date:  2004-08       Impact factor: 4.705

10.  Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial.

Authors:  Michael J Kovacs; Marc Rodger; David R Anderson; Beverly Morrow; Gertrude Kells; Judy Kovacs; Eleanor Boyle; Philip S Wells
Journal:  Ann Intern Med       Date:  2003-05-06       Impact factor: 25.391

View more
  1 in total

1.  Inpatient warfarin management: pharmacist management using a detailed dosing protocol.

Authors:  Nancy L Dawson; Ivan E Porter; Dusko Klipa; William R Bamlet; Mary Ann Hedges; Michael J Maniaci; Jason Persoff; Archana Roy; Alden V Patel
Journal:  J Thromb Thrombolysis       Date:  2012-02       Impact factor: 2.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.